ResMed (RMD) Tops Q2 EPS by 3c
Get Alerts RMD Hot Sheet
Price: $178.85 +0.70%
Revenue Growth %: +4.8%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +4.8%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $0.73, $0.03 better than the analyst estimate of $0.70. Revenue for the quarter came in at $530.4 million versus the consensus estimate of $515.94 million.
"We had a strong quarter with 18 percent constant currency revenue growth led by solid growth in our Brightree software offerings and global device sales," said Mick Farrell, ResMed's CEO
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
- Growth isn't weak enough to truly undercut inflation pressures - BMO
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!